Abstract
Objective To evaluate the potential clinical value of quantitative functional FDG PET and pathological amyloid-β PET with cerebrospinal fluid (CSF) biomarkers and clinical assessments in the prediction of Alzheimer's disease (AD) progression.
| Original language | English |
|---|---|
| Article number | e0154406 |
| Journal | PloS one |
| Volume | 11 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2016 |